ISRCTN68864186已完成3 期
Multicentre, prospective, assessor-blind, in parallel groups randomised and versus reference marketed product controlled confirmatory trial of the efficacy and safety of Institut Biochimique SA (IBSA) 0.1% betamethasone valerate (BMV) medicated plaster for the treatment of chronic plaque psoriasis
Institut Biochimique SA (IBSA) (Switzerland)0 个研究点目标入组 180 人开始时间: 2010年2月11日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Subjects (outpatients) of both genders
- •2. Aged 18 years or more
- •3. Suffering from stable chronic plaque psoriasis (psoriasis vulgaris), involving less than 10% of the body surface area (BSA) (i.e. mild to moderate psoriasis according to CHMP/EWP/2454/02corr19) and presenting with psoriatic plaques in extensory skin areas, i.e. elbow and/or knee
- •4. Have at least two plaques on extensory parts of limbs that must be each greater than or equal to 10 cm^2 but less than 150 cm^2 (surface area equivalent of two BMV medicated plasters). These plaques, defined as target areas, will be treated with the tested formulation, BMV medicated plaster, or with the comparator product, BMV 0.1% cream (not occluded), according to a computer generated, fully randomised sequence. When present, other affected skin areas, different from those identified as target plaques, will be treated only with a bland emollient (5% urea) during the whole treatment period.
- •5. Female subjects of childbearing potential (i.e., not status post hysterectomy or tubal ligation) must use an appropriate method of contraception according to the definition of Note 3 of ICH M3 Guideline; pregnant or breast-feeding women will not be included
- •6. Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
- •7. Ability to cooperate with the Investigator and to comply with the requirements of the entire study
- •8. Signed written informed consent prior to inclusion in the study
排除标准
- •1. Guttate, pustular or other non-plaque form of psoriasis
- •2. More severe stage of chronic plaque psoriasis, needing a systemic therapeutic approach in order to control the disease and not amenable to topical treatment
- •3. No concurrent dermatological conditions that could interfere with the assessment of the psoriatic lesion
- •4. No underlying disease or medication that severely compromise the patient's immune system
- •5. No history of anaphylaxis to drugs or allergic reactions in general, which the Investigator considers to potentially affect the outcome of the study
- •6. No use of topical anti-psoriatic drugs during the two weeks before inclusion in this study
- •7. No use of a topical retinoids during the 4 weeks before inclusion in this study
- •8. No systemic antipsoriatic therapy (e.g. corticosteroids - including intralesional corticosteroid, vitamin D in high doses, vitamin D analogs, methotrexate, cyclosporin, UVB programs or UVA/psoralen programs) within 4 weeks before inclusion
- •9. No participation in the evaluation of any investigational drug during 3 months before the study
研究者
相似试验
已完成
不适用
Comparison of efficacy and safety of Betesil® medicated plaster versus Daivobet®/Dovobet® ointment in the treatment of chronic plaque psoriasisChronic plaque psoriasisSkin and Connective Tissue DiseasesPsoriasisISRCTN34974208Institut Biochimique SA (IBSA) (Switzerland)300
进行中（未招募）
不适用
Multicentre, prospective, assessor-blind, in parallel groups randomised and vs reference marketed product controlled confirmatory trial of the efficacy and safety of IBSA BMV medicated plaster for the treatment of chronic plaque psoriasischronic plaque psoriasisMedDRA version: 9.1Level: LLTClassification code 10033898Term: ParapsoriasisEUCTR2005-003050-96-ITIBSA180
进行中（未招募）
不适用
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet/Dovobet, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis. - NDEUCTR2009-016969-28-ITIBSA INSTITUT BIOCHIMIQUE SA300
进行中（未招募）
1 期
Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50µg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis.EUCTR2009-016969-28-FRIBSA, Institut Biochimique SA
已完成
3 期
A Phase III clinical trial of Teriparatide in postmenopausal women with osteoporosisCTRI/2021/04/032769Intas Pharmaceuticals Ltd